Compellon

About Compellon

Founded in 2010 by Mark Pollard and Nikolai Liachenko, Compellon operated as a predictive analytics company based in California. The firm specialized in re-engineering predictive modeling through artificial intelligence, developing technology designed to remove technical burdens from users. Compellon's platform was engineered to help businesses move from descriptive to prescriptive analytics, enabling them to understand not just what has happened but what actions to take. The company secured $12.1 million in total funding over seven rounds, with Kairos Ventures as a notable institutional investor.

Compellon's core product, Compellon20|20, was a 'clear-box' analytics platform powered by proprietary 'Plug and Play AI'. This software automated processes like data cleaning, transformation, and feature engineering, which significantly reduced the time to gain insights. The platform's features included identifying key drivers for business outcomes, building explainable custom models for confident predictions, and recommending tactical actions. It was designed for business analysts, allowing them to perform root cause analysis, predict risks, and gain customer insights without needing deep technical expertise. The company served a range of clients, from Fortune 500 companies to more specialized vertical market players, primarily in sectors like retail, e-commerce, and customer experience.

In September 2021, Compellon was acquired by Clearsense, a healthcare-focused AI data analytics platform. The acquisition was a strategic move for Clearsense to integrate Compellon's predictive modeling solution into its end-to-end analytics platform. This integration aimed to empower healthcare professionals and other users to solve clinical and business problems more efficiently, making data analytics more accessible and reducing the time required to test hypotheses from weeks to hours. The deal positioned Compellon's technology as a cornerstone of Clearsense's advanced analytics and research offerings, contributing to the rise of the 'citizen data scientist' in the healthcare industry.